➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Medtronic
Dow
Mallinckrodt
Baxter

Last Updated: July 14, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ALPRAZOLAM

» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Alprazolam

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00004373 Phase II Double-Blind, Placebo-Controlled Study of the Reinforcing Effects of Alprazolam in Patients With Anxiety Completed University of Texas Phase 2 1997-03-01 OBJECTIVES: I. Determine whether the benzodiazepine alprazolam reinforces self-medication behavior in anxious patients with varying histories of using other drugs. II. Establish outpatient methods for the study of self-medication and drug reinforcement in patients vulnerable to prescription drug abuse or dependence. III. Evaluate the influence of alcohol and other non-prescription drug use as determinants of vulnerability in these patients. IV. Identify personality, attitudinal, or other variables that might predict different patterns of self-medication. V. Assess the effects of cognitive-behavioral therapy on alprazolam self-medication.
NCT00004373 Phase II Double-Blind, Placebo-Controlled Study of the Reinforcing Effects of Alprazolam in Patients With Anxiety Completed National Institute on Drug Abuse (NIDA) Phase 2 1997-03-01 OBJECTIVES: I. Determine whether the benzodiazepine alprazolam reinforces self-medication behavior in anxious patients with varying histories of using other drugs. II. Establish outpatient methods for the study of self-medication and drug reinforcement in patients vulnerable to prescription drug abuse or dependence. III. Evaluate the influence of alcohol and other non-prescription drug use as determinants of vulnerability in these patients. IV. Identify personality, attitudinal, or other variables that might predict different patterns of self-medication. V. Assess the effects of cognitive-behavioral therapy on alprazolam self-medication.
NCT00029263 Screening Herbs for Drug Interactions Completed National Center for Complementary and Integrative Health (NCCIH) Phase 2 2001-08-01 The purpose of this study is to detect potential herb-drug interactions in volunteers.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Alprazolam

Condition Name

Condition Name for Alprazolam
Intervention Trials
Healthy 23
Panic Disorder 6
ANXIETY 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Alprazolam
Intervention Trials
Anxiety Disorders 15
Disease 10
Panic Disorder 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Alprazolam

Trials by Country

Trials by Country for Alprazolam
Location Trials
United States 96
France 8
Mexico 4
United Kingdom 4
Iran, Islamic Republic of 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Alprazolam
Location Trials
North Dakota 7
Maryland 6
Pennsylvania 5
Kansas 5
New York 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Alprazolam

Clinical Trial Phase

Clinical Trial Phase for Alprazolam
Clinical Trial Phase Trials
Phase 4 18
Phase 3 5
Phase 2/Phase 3 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Alprazolam
Clinical Trial Phase Trials
Completed 49
Recruiting 12
Not yet recruiting 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Alprazolam

Sponsor Name

Sponsor Name for Alprazolam
Sponsor Trials
Pfizer 18
GlaxoSmithKline 5
National Institute on Drug Abuse (NIDA) 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Alprazolam
Sponsor Trials
Industry 50
Other 41
NIH 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
McKesson
Mallinckrodt
Baxter
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.